About US
Contact us
-
Roche chairman pooh-poohs another Illumina bidIf you've been rooting for Roche ($RHHBY) to make another run at the gene sequencing company Illumina ($ILMN), you could be in for a disappointment. The drugmaker's chairman, Franz Humer, told a Swis2013/1/8
-
Takeda, Affymax nail supply deal for Omontys anemia drugTakeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to tre2013/1/8
-
Evotec Acquires Cell Culture ServiceEvotec AG has acquired Cell Culture Service GmbH (CCS), based in Hamburg, Germany, for $1.5 million in cash and an earn-out payment of $1.4 million in cash. CCS supplies custom cells and cell-based r2013/1/7
-
NGM, Janssen in Diabetes Discovery AllianceNGM Biopharmaceuticals has signed a worldwide agreement with Janssen Pharmaceuticals to discover and develop therapeutics for the potential treatment of Type 2 diabetes and other metabolic diseases.2013/1/7
-
AstraZeneca in Discovery Pact with Cellular DynamicsCellular Dynamics International, Inc. (CDI) entered a Center of Excellence agreement with AstraZeneca to accelerate drug discovery efforts using human induced pluripotent stem cell (iPSC) lines and t2013/1/6
-
AbbVie Launches New Biopharma CompanyAbbVie has launched as an independent biopharmaceutical company, as Abbott completed the separation from the research arm of its pharmaceutical business. AbbVie launches with an estimated $18 billion2013/1/6
-
India set to rule in Novartis patent caseIndia's Supreme Court is expected to rule soon on a patent for Novartis' ($NVS) groundbreaking cancer treatment Gleevec, and Big Pharma and international aid groups are waiting with bated breath to s2013/1/5
-
Much goes into pricing a drug at $295,000So what goes into landing on $295,000 as the annual cost of a drug that maybe only 3,000 patients a year will use? That is the price tag that NPS Pharmaceuticals ($NPSP) has put on the recently appro2013/1/5
-
Lilly first to defend against DES litigationFifty to 80 years ago, the synthetic estrogen DES was commonly prescribed to women who were at risk for miscarriage and premature births. Now dozens of their daughters who have developed breast cance2013/1/4
-
Study ties drug shortages to cancer relapsesDrug shortages have been of grave concern to cancer patients for whom the right drugs can be a matter of life or death. Now there is a published study that documents that a drug shortage can effect l2013/1/4